Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Gathers Leads at Events, Notes Rapid Market Expansion

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biopharmaceuticals, nutraceuticals, cosmetics, agrochem, and food/beverage industries, is reporting more than 60 strong leads gathered from its participation at two cannabis drink expo events, one in San Francisco and one in Chicago. The positive response is indicative of the rapid market expansion and potential for cannabis beverages, the company observes. Company officials also noted that a common theme at both events was the need for faster, more effective delivery of cannabis dosing with reliably repeatable precision. PBI’s patented Ultra Shear Technology(TM) (“UST”) platform for the nanoemulsification of CBD and other cannabinoids provides that solution. The company noted that seven companies requested immediate discussions and follow-up on the potential for incorporating UST in their product lines quickly as possible. “This was our first time participating in cannabis-focused expositions, and it was a resounding success,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “Last month we announced our plan and forecast to have a minimum of six UST nanoemulsion toll-processing contracts in place by the close of 2022. Based on the immediate traction gained in these two cannabis beverage meetings, and the feedback to date from our consortium colleagues at The Ohio State University focusing on UST introductions and rapid penetration into the food and beverages industry, we have increased our guidance to a total of 12 UST contracts to be closed by the end of 2022. We believe that each of these new contracts will offer $1 million or more per year in incremental revenue to PBI in 2023 and beyond.”

To view the full press release, visit

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating, or pressure cycling technology (“PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counterbioterror applications. Additionally, major new market opportunities have emerged for the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in Pressure BioSciences Inc. PBIO. Bookmark the permalink.

Comments are closed.